Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLM) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 561,000 shares, a drop of 79.9% from the August 15th total of 2,790,000 shares. Based on an average trading volume of 3,930,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.9% of the company’s stock are sold short.

Apollomics Stock Performance

Shares of Apollomics stock traded up $0.00 during trading on Thursday, reaching $0.14. The stock had a trading volume of 97,400 shares, compared to its average volume of 1,641,516. Apollomics has a 52 week low of $0.11 and a 52 week high of $4.27. The stock has a fifty day moving average price of $0.16 and a two-hundred day moving average price of $0.35.

Institutional Trading of Apollomics

An institutional investor recently bought a new position in Apollomics stock. Powell Investment Advisors LLC acquired a new position in shares of Apollomics, Inc. (NASDAQ:APLM) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned about 0.15% of Apollomics at the end of the most recent reporting period. 19.13% of the stock is currently owned by hedge funds and other institutional investors.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.